CLDX Celldex Therapeutics, Inc.
Healthcare$30.72+0.00%OpenMarket Cap: $2.04B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.48
P/S
2493.57
EV/EBITDA
-6.71
DCF Value
$0.23
FCF Yield
-11.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-4.1%
Operating Margin
-37694.6%
Net Margin
-34596.2%
ROE
-50.7%
ROA
-55.5%
ROIC
-67.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $15.0K | -5593.3% | $-84.4M | $-78.7M | $— | — |
| Q4 null | $75.0K | 100.0% | $-87.2M | $-81.4M | $— | — |
| FY null | $1.5M | 100.0% | $-287.4M | $-258.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-73.6M | $-67.0M | $— | — |
| Q2 null | $730.0K | 100.0% | $-63.9M | $-56.6M | $— | — |
| Q1 null | $695.0K | 100.0% | $-62.7M | $-53.8M | $— | — |
| Q4 null | $1.2M | 30.3% | $-56.0M | $-47.1M | $— | — |
| FY null | $7.0M | -2229.8% | $-195.1M | $-157.9M | $— | — |
| Q3 null | $3.2M | 100.0% | $-52.1M | $-42.1M | $— | — |
| Q2 null | $2.5M | 68.1% | $-46.3M | $-35.8M | $— | — |
| Q1 null | $156.0K | -396.8% | $-40.6M | $-32.8M | $— | — |
| Q4 2023 | $4.1M | -636.5% | $-47.6M | $-43.3M | $-0.83 | — |